| Trial ID: | L6501 |
| Source ID: | NCT01575483
|
| Associated Drug: |
No Intervention (Subjects Were Previously Treated With Onglyza®)
|
| Title: |
Korean Post-marketing Surveillance for Onglyza®
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: No Intervention (subjects were previously treated with Onglyza®)
|
| Outcome Measures: |
Primary: Adverse events occurrence, 30 days after last dose of study drug | Secondary: Number of Adverse Events and Serious Adverse Events, 30 days after last dose of study drug|Effectiveness of Onglyza® measured by Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2-hr post-prandial glucose (2-hr PPG) comparing baseline data, Baseline (Week 0), 12 weeks and 24 weeks of registration
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3433
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2012-03-01
|
| Completion Date: |
2016-09-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-08
|
| Locations: |
Research Site, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01575483
|
